Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

Phase 2

Completed

• Conditions: Warts

• Registration Number: NCT00114920
• Lead Sponsor: Graceway Pharmaceuticals, LLC

Brief Summary

The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for twelve weeks.

A second purpose is to evaluate the safety of the drug.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-03
• Study First Submitted: 2005-06-20
• Study First Submitted QC: 2005-06-20
• Study First Posted: 2005-06-21
• Status Verified: 2006-11
• Last Update Submitted: 2007-02-16
• Last Update Posted: 2007-02-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

• Diagnosis of common warts
• Two forms of birth control

Exclusion Criteria

• Pregnant or breast feeding
• Other types of wart(s), ie. plantar
• Currently participating in another clinical study
• Chronic viral hepatitis B or C

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Clearance of treated common wart(s)

Secondary Outcome Measures

Name	Time	Method
Partial clearance of treated common wart(s)
Wart recurrence

Trial Locations

Locations (1)

Welborn Clinic; 🇺🇸 Evansville, Indiana, United States